1.
|
Phase: Phase IV Type: Prevention Status: Closed Age: 10 to 18 Sponsor: Other Protocol IDs: BMGF48979, ISRCTN98283094, REFCTRI-2009 000137, NCT00923702
|
|
2.
|
Phase: Phase IV Type: Prevention Status: Completed Age: 9 to 26 Sponsor: Other Protocol IDs: 09-000485, NCT01034358
|
|
3.
|
Phase: Phase IV Type: Health services research, Natural history/Epidemiology, Prevention Status: Completed Age: 9 and over Sponsor: Other Protocol IDs: MITU-001, NCT01173900
|
|
4.
|
Phase: Phase IV Type: Prevention Status: Closed Age: 16 to 26 Sponsor: Pharmaceutical / Industry Protocol IDs: V501-110, NCT01544478
|
|
5.
|
Phase: Phase III Type: Prevention Status: Closed Age: 24 to 45 Sponsor: Pharmaceutical / Industry Protocol IDs: V501-019, 2004_013, NCT00090220
|
|
6.
|
Phase: Phase III Type: Prevention Status: Completed Age: 11 to 17 Sponsor: Pharmaceutical / Industry Protocol IDs: 2005_092, V501-025, NCT00325130
|
|
7.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 11 to 17 Sponsor: Pharmaceutical / Industry Protocol IDs: 2005_093, V501-024, NCT00337428
|
|
8.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 18 to 45 Sponsor: Pharmaceutical / Industry Protocol IDs: 108933, NCT00423046
|
|
9.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 9 to 15 Sponsor: Pharmaceutical / Industry Protocol IDs: 2006_038, V501-029, NCT00380367
|
|
10.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 9 to 26 Sponsor: Pharmaceutical / Industry Protocol IDs: V501-030, 2007_021, NCT00496626
|
|
11.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 9 to 26 Sponsor: Other Protocol IDs: H07-00928, BCGov-01, NCT00501137
|
|
12.
|
Phase: Phase III Type: Prevention Status: Closed Age: 16 to 26 Sponsor: Pharmaceutical / Industry Protocol IDs: 2007_538, V503-001, NCT00543543
|
|
13.
|
Phase: Phase III Type: Prevention Status: Completed Age: 12 to 26 Sponsor: Other Protocol IDs: RCH CA27091, NCT00964210
|
|
14.
|
Phase: Phase III Type: Prevention Status: Closed Age: 9 to 26 Sponsor: Pharmaceutical / Industry Protocol IDs: V501-046, NCT01245764
|
|
15.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 16 to 23 Sponsor: Pharmaceutical / Industry Protocol IDs: 2005_086, V502-001, NCT00260039
|
|
16.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 9 to 17 Sponsor: Pharmaceutical / Industry Protocol IDs: V501-028, 2006_052, NCT00411749
|
|
17.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: CDR0000559149, AMC-052, U01CA121947, 052, NCT00513526
|
|
18.
|
Phase: Phase II Type: Prevention Status: Completed Age: 16 to 26 Sponsor: Pharmaceutical / Industry Protocol IDs: 2007_567, V505-001, NCT00520598
|
|
19.
|
Phase: Phase II Type: Prevention Status: Completed Age: 16 to 26 Sponsor: Pharmaceutical / Industry Protocol IDs: 2007_566, V504-001, NCT00551187
|
|
20.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Prevention Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CDR0000593634, U01CA121947, AMC-054, NCT00667563
|
|
21.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Prevention Status: Closed Age: 12 to 26 Sponsor: NCI Protocol IDs: 090024, 09-C-0024, NCI-09-C-0024, NCI-P07277, NCT00798265
|
|
22.
|
Phase: Phase I Type: Educational/Counseling/Training, Prevention, Screening Status: Completed Age: 10 to 13 and 30 to 45 Sponsor: Other Protocol IDs: PERCAPS I, NCT01338051
|
|
23.
|
Phase: No phase specified Type: Natural history/Epidemiology, Prevention Status: Enrolling by invitation Age: 18 to 26 Sponsor: Other Protocol IDs: DDEAMC 07-43X, NCT00501189
|
|
24.
|
Phase: No phase specified Type: Diagnostic, Prevention Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: #33245, NCT00666107
|
|
25.
|
Phase: No phase specified Type: Natural history/Epidemiology, Prevention Status: Completed Age: 12 to 13 Sponsor: Other Protocol IDs: Vaccine HCB 01, NCT01159834
|